Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Neuralstem Phase I Results Encourage Market, Stimulates Buying

By Myriad Equity Stock MarketsMay 22, 2013 03:12AM ET
www.investing.com/analysis/neuralstem-phase-i-results-encourage-market,-stimulates-buying-167941
Neuralstem Phase I Results Encourage Market, Stimulates Buying
By Myriad Equity   |  May 22, 2013 03:12AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Although it seems that investors have lost their appetite for many stem cell investments at this stage of the broader rally in the stock market, there are exceptions worth pointing out. Neuralstem (CUR), for instance, has been in a strong uptrend since the company finally on April 17th that the company received approval from the FDA to commence a Phase II clinical trial in 18 patients with ALS (amyotrophic lateral sclerosis) using its line of spinal-cord derived stem cells NSI-566. These proprietary stem cells can be differentiated into neurons, which can (in theory) replace the dying cells in a patient with a neurodegenerative disease.

Although the jump from Phase I to Phase II development is not a reliable guarantee of eventual success for any therapy, this marks an important milestone for the company and also establishes the initial safety profile for Neuralstem’s NSI-566. The market became particularly enamored with shares of CUR after the company presented the results of the early stage ALS trial.

The trial, which was conducted on 15 patients with ALS, started in early 2010 and concluded only recently. According to PI Eva Feldman in a recent Neuralstem press release, 6 of the patients in the study experienced stability, slow progression, or even improved disease course 700 to 850 days after implantation with NSI-566 cells. The remaining 9 saw no noticeable improvements, while 6 patients died of ALS within the first few months after the surgery.

The results imply that the therapy is very effective against the progression of ALS given that NSI-566 is introduced early on, which is very exciting due to the complete lack of any treatment alternatives for ALS patients. Having said this, investors should not make any conclusions about any drug or therapy’s efficacy in any particular disease without the numbers behind the Phase I results – especially with such a tiny patient population. More specifically, we will want to compare the improvements in the 6 patients relative to the others based on the ALSFRS (Amyotrophic Lateral Sclerosis Functional Rating Scale) in any ways possible to determine whether or not this kind of result can be replicated in future clinical trials with enough statistical significance to give NSI-566 an approval for the ALS indication later on.

The upcoming Phase II trial, which is expected to begin before the end of the H1 2013, should be watched closely since it will demonstrate to Neuralstem investors and the rest of the market whether or not the company can replicate the implied efficacy in the Phase I studies with NSI-566. The company’s market capitalization, just short of $100M, is likely to jump significantly if the Phase II trial produces similar results and much more down the line (presumably during Phase III development) due to the sheer size of the untouched multi-billion ALS market.

And, if Neuralstem can provide a working ALS treatment that can slow or even reverse the course of the disease based on the ALSFRS, it is unlikely that the company would have much trouble achieving extremely high market penetration and pricing power with even a modest budget for SG&A expenses. This would hopefully allow NSI-566 to avoid the kind of problems that Dendreon’s (DNDN) Provenge therapy had, although manufacturing costs have proven burdensome as well.

Also baked into the $100M valuation is NSI-566’s development into a number of other indications that have significant unmet need, although the market seems fixated on ALS due to the unique affinity that Neuralstem’s product seems to have for this disease. It’s because of this that I generally expect less movement in shares of CUR in reaction to non-ALS related headlines coming out from the company, and exaggerated reactions to third party opinion regarding the program going forward.

Neuralstem Phase I Results Encourage Market, Stimulates Buying
 

Related Articles

Neuralstem Phase I Results Encourage Market, Stimulates Buying

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email